Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer’s Disease Through Inhibition of BACE1
Tóm tắt
A number of epidemiological studies have established a link between Alzheimer’s disease (AD) and diabetes mellitus (DM). So, nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) plays an important role in the treatment of AD. However, current PPARγ-targeting drugs such as thiazolidinediones (TZDs) are associated with undesirable side effects. We identified herbal extract with a small molecular, astragaloside IV (AS-IV), as a selective PPARγ natural agonist in nervous cells by developing a PPAR-PPRE pathway regulatory system. Cultured SH-SY5Y cells transfected with pEGFP-N1-BACE1 were treated with AS-IV for 24 h or AS-IV plus the PPAR-γ antagonist GW9662 in vitro. APP/PS1 mice were intragastrically treated with AS-IV or AS-IV plus the GW9662 every 48 h for 3 months. Immunofluorescence, western blotting, and real-time PCR were used to examine the expression of PPARγ and BACE1. Immunohistochemical staining was performed to analyze the distribution of Aβ plaques in the APP/PS1 mouse brain. The levels of Aβ were determined using ELISA kits. AS-IV was shown to be a PPARγ agonist by establishing a high-throughput screening model for PPARγ agonists. The results showed that AS-IV treatment increased activity of PPARγ and inhibited BACE1 in vitro. As a result, Aβ levels decreased significantly. GW9662, which is a PPARγ antagonist, significantly blocked the beneficial role of AS-IV. In vivo, AS-IV treatment increased PPARγ and BACE1 expression and reduced neuritic plaque formation and Aβ levels in the brains of APP/PS1 mice. These effects of AS-IV could be effectively inhibited by GW9662. These results indicate that AS-IV may be a natural PPARγ agonist that suppressed activity of BACE1 and ultimately attenuates generation of Aβ. Therefore, AS-IV may be a promising agent for modulating Aβ-related pathology in AD.
Tài liệu tham khảo
Nardo L, Re F, Brioschi S, Cazzaniga E, Orlando A, Minniti S, Lamperti M, Gregori M et al (2016) Fluorimetric detection of the earliest events in amyloid beta oligomerization and its inhibition by pharmacologically active liposomes. Biochim Biophys Acta 1860(4):746–756. doi:10.1016/j.bbagen.2016.01.003
Grimm MO, Mett J, Stahlmann CP, Grosgen S, Haupenthal VJ, Blumel T, Hundsdorfer B, Zimmer VC et al (2015) APP intracellular domain derived from amyloidogenic beta- and gamma-secretase cleavage regulates neprilysin expression. Front Aging Neurosci 7:77. doi:10.3389/fnagi.2015.00077
Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol 41(6):1261–1268. doi:10.1016/j.biocel.2008.12.015
Mittal K, Katare DP (2016) Shared links between type 2 diabetes mellitus and Alzheimer’s disease: a review. Diabetes & Metabolic Syndrome. doi:10.1016/j.dsx.2016.01.021
Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, Ricobaraza A, Perez-Mediavilla A et al (2010) Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35(7):1593–1604. doi:10.1038/npp.2010.32
Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci 32(30):10117–10128. doi:10.1523/JNEUROSCI.5268-11.2012
Nicolakakis N, Hamel E (2010) The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer’s Disease. Frontiers in Aging Neuroscience 2. doi:10.3389/fnagi.2010.00021.
Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, Beckett TL, Murphy MP et al (2012) Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer’s disease. J Alzheimers Dis 30(4):943–961. doi:10.3233/JAD-2012-111661
Liu F, Wang Y, Yan M, Zhang L, Pang T, Liao H (2013) Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. Neurosci Lett 557(Pt B):90–94. doi:10.1016/j.neulet.2013.10.052
Sastre M, Klockgether T, Heneka MT (2006) Contribution of inflammatory processes to Alzheimer’s disease: molecular mechanisms. Int J Dev Neurosci 24(2-3):167–176. doi:10.1016/j.ijdevneu.2005.11.014
Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y et al (2009) Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 106(10):3907–3912. doi:10.1073/pnas.0807991106
Zou C, Hu H (2013) Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk. Vasc Health Risk Manag 9:429–433. doi:10.2147/VHRM.S34421
Chen Y, Gui D, Chen J, He D, Luo Y, Wang N (2014) Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats. Cell Physiol Biochem 33(6):1975–1987. doi:10.1159/000362974
Chen J, Chen Y, Luo Y, Gui D, Huang J, He D (2014) Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats. Eur J Pharmacol 736:86–94. doi:10.1016/j.ejphar.2014.04.037
Xu ME, Xiao SZ, Sun YH, Ou-Yang Y, Zheng XX (2006) Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro. Acta Pharmacol Sin 27(2):229–236. doi:10.1111/j.1745-7254.2006.00243.x
Kim S, Kang IH, Nam JB, Cho Y, Chung DY, Kim SH, Kim JS, Cho YD et al (2015) Ameliorating the effect of astragaloside IV on learning and memory deficit after chronic cerebral hypoperfusion in rats. Molecules 20(2):1904–1921. doi:10.3390/molecules20021904
Sun Q, Jia N, Wang W, Jin H, Xu J, Hu H (2014) Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening. PLoS ONE 9(6):e98866. doi:10.1371/journal.pone.0098866
Zhou W, Cai F, Li Y, Yang GS, O’Connor KD, Holt RA, Song W (2010) BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer’s disease. J Mol Neurosci 42(1):127–133. doi:10.1007/s12031-010-9381-6
Zhang ZG, Wu L, Wang JL, Yang JD, Zhang J, Zhang J, Li LH, Xia Y et al (2012) Astragaloside IV prevents MPP(+)-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem 364(1-2):209–216. doi:10.1007/s11010-011-1219-1
Liu HS, Shi HL, Huang F, Peterson KE, Wu H, Lan YY, Zhang BB, He YX et al (2016) Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway. Sci Rep 6:19137. doi:10.1038/srep19137
Li WZ, Wu WY, Huang DK, Yin YY, Kan HW, Wang X, Yao YY, Li WP (2012) Protective effects of astragalosides on dexamethasone and Abeta25-35 induced learning and memory impairments due to decrease amyloid precursor protein expression in 12-month male rats. Food Chem Toxicol 50(6):1883–1890. doi:10.1016/j.fct.2012.03.064
Cheng H, Shang Y, Jiang L, Shi TL, Wang L (2016) The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: a meta-analysis. Int J Neurosci 126(4):299–307. doi:10.3109/00207454.2015.1015722
Heneka MT, Fink A, Doblhammer G (2015) Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 78(2):284–294. doi:10.1002/ana.24439
Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, Liao MX, Ding QL et al (2012) PPARgamma agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther 18(8):659–666. doi:10.1111/j.1755-5949.2012.00341.x
Tan NS, Michalik L, Desvergne B, Wahli W (2005) Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol 93(2-5):99–105. doi:10.1016/j.jsbmb.2004.12.025
Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S (2011) The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Advanced Pharmaceutical Technology & Res 2(4):236–240. doi:10.4103/2231-4040.90879
Chen LM, Lin ZY, Zhu YG, Lin N, Zhang J, Pan XD, Chen XC (2012) Ginsenoside Rg1 attenuates beta-amyloid generation via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695 cells. Eur J Pharmacol 675(1-3):15–21. doi:10.1016/j.ejphar.2011.11.039
Hu J, Lin T, Gao Y, Xu J, Jiang C, Wang G, Bu G, Xu H et al (2015) The resveratrol trimer miyabenol C inhibits beta-secretase activity and beta-amyloid generation. PLoS ONE 10(1):e0115973. doi:10.1371/journal.pone.0115973
Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE et al (2006) Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103(49):18727–18732. doi:10.1073/pnas.0606298103
Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O’Connor T, Logan S, Maus E et al (2007) Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer’s disease pathogenesis. J Neurosci 27(14):3639–3649. doi:10.1523/JNEUROSCI.4396-06.2007
Wang X, Zheng W, Xie JW, Wang T, Wang SL, Teng WP, Wang ZY (2010) Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 5:46. doi:10.1186/1750-1326-5-46
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L et al (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103(2):443–448. doi:10.1073/pnas.0503839103
Wang X, Yu S, Wang CY, Wang Y, Liu HX, Cui Y, Zhang LD (2015) Advanced glycation end products induce oxidative stress and mitochondrial dysfunction in SH-SY5Y cells. In Vitro Cell Dev Biol Anim 51(2):204–209. doi:10.1007/s11626-014-9823-5
Wang CY, Xie JW, Xu Y, Wang T, Cai JH, Wang X, Zhao BL, An L et al (2013) Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-kappaB pathway in a transgenic mouse model of Alzheimer’s disease. Antioxid Redox Signal 19(17):2024–2039. doi:10.1089/ars.2012.5158